Method for screening candidate compounds for antitumor drug

Details Method for screening candidate compounds for antitumor drug Method for screening candidate compounds for antitumor drug

2006-09-15

2010-12-28

Yu, Misook (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving transferase

Reexamination Certificate

active

07858333

ABSTRACT:
Investigation on the frequency of FLT3/ITD found in various blood cancers has revealed that the frequency is high in acute myeloblastic leukemia in particular. Studies on the effects of FLT3/ITD in the blood cell lines revealed that the tyrosine residues in FLT3/ITD is constitutively phosphorylated in these cell lines and that blood cells into which FLT3/ITD is introduced show IL-3 independent proliferation. Moreover, the blood cells into which FLT3/ITD is introduced are found to be capable of forming tumors and inhibit cell differentiation. The inventors have found that it is possible to screen for pharmaceutical compounds against tumors by using inhibition of these FLT3/ITD functions as an index.

REFERENCES:
patent: 5635388 (1997-06-01), Bennett et al.
patent: 5821227 (1998-10-01), Dennis et al.
patent: 5830671 (1998-11-01), Dennis et al.
patent: 5981483 (1999-11-01), Dennis et al.
patent: 2258022 (1998-01-01), None
patent: 9-512910 (1997-12-01), None
patent: WO 97/33995 (1997-09-01), None
patent: WO 98/00713 (1998-01-01), None
Carow et al (1996, Blood, vol. 87, pp. 1089-1096).
Yokota et al., Leukemia, “Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines,” vol. 11, pp. 1605-1609, 1997, Stockton Press.
Kiyoi et al., Leukemia,“ Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia,” vol. 11, pp. 1447-1452, 1997, Stockton Press.
Nakao et al., Leukemia, “Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia,” vol. 10, pp. 1911-1918, 1996, Stockton Press.
Kiyoi et al., “FLT3 in Human Hematologic Malignancies,” Leukemia and Lymphoma, vol. 43, No. 8, 2002, Taylor & Francis Ltd., pp. 1541-1547.
Zhao et al., “In Vivo Treatment of Mutant FLT3-Transformed Murine Leukemia with a Tyrosine Kinase Inhibitor,” Leukemia, vol. 14, 2000, Macmilan Publishers Ltd., pp. 374-378.
Serve et al., Int. J. Oncol., 1999, 14(4)765-770.
Lemola et al., Blood, 1991, 77:1829-1836.
Kiyoi et al., Leukemia, 1998, 12:1333-1337.
Teller et al., Leukemia, 2002, 16:1528-1534.
Carow et al., Blood, 1996, 87:1089-1096.
Li et al., PNAS, 1992, 89:3315-3319.
Beslu et al., “Phosphatidylinositol-3' Kinase is not Required for Mitogenesis or Internalization of the Flt3/Flk2 Receptor Tyrosine Kinase,” J. Biol. Chem., Aug. 16, 1996, 271(33):20075-20081.
Dosil et al., “Mitogenic Signalling and Substrate Specificity of the Flk2/Flt3 Receptor Tyrosine Kinase in Fibroblasts and Interleukin 3-Dependent Hematopoietic Cells,” Molecular and Cellular Biology, Oct. 1993, 13(10):6572-6585.
Hayakawa et al., “Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines,” Oncogene, 2000, 19:624-631.
Kumagai et al., “A screen for selective inhibitors on mutated FLT3 signal transduction pathway,” Nihon Gangakkai Sokai Kiji, Sep. 26, 2001, 60, p. 220, 611, with English translation, 1 page.
Murata et al., “Selective Cytotoxic Mechanism of GTP-14564, a Novel Tyrosine Kinase Inhibitor in Leukemia Cells Expressing a Constitutively Active Fms-like Tyrosine Kinase 3 (FLT3)*,” J. Biol. Chem., Aug. 29, 2003, 278(35):32892-32898.

Affiliated with

Also associated with

Rating

Method for screening candidate compounds for antitumor drug does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for screening candidate compounds for antitumor drug, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for screening candidate compounds for antitumor drug will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4182409